Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the main cause of dementia in the elderly population. Since the treatment of AD has been associated with the activity of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), their inhibitors remain the main focus of AD investigations. In this study we evaluated cholinesterase inhibitory activity of 14 bicyclo[3.2.1]octene/octadiene derivatives and naturally occurring sesquiterpene alcohol cedrol. These 14 compounds have been efficiently and ecologically prepared by a photochemical approach in batch photochemical reactors. Various compounds with the bicyclo[3.2.1]octene skeleton have already been successfully evaluated for treatment of central nervous system disorders and AD. Among the tested polycyclic derivatives, compounds 4-[(9$S)$-tricyclo[6.3.1.0$^{2,7}$]dodeca-2,4,6,10-tetraen-9-yl]pyridine (\textbf{3}) and (11$S)$-11-(4-chlorophenyl)-12-[($E)$-2-(4-chlorophenyl)ethenyl]tricyclo[6.3.1.0$^{2,7}$]dodeca-2,4,6,9-tetraene (\textbf{6}) showed the best inhibitory activity on BChE (IC$_{50}$ = 8.8 $\mu $M) and AChE (IC$_{50}$ = 17.5 $\mu $M), respectively.
Highlights
Alzheimer’s disease (AD) is one of the most common neurodegenerative disorders and causes of dementia in Western society, mostly affecting the elderly population
The World Health Organization (WHO) estimates that AD affects over 50% of people older than 85 [1,2,3]
The most prominent symptom of this disease is a progressive decrease in cognitive function, which in turn leads to changes in behavioral patterns and a decrease in the functional capacity of the affected individuals
Summary
Alzheimer’s disease (AD) is one of the most common neurodegenerative disorders and causes of dementia in Western society, mostly affecting the elderly population. Among the 14 bicyclo[3.2.1]octenes/octadienes tested, all the compounds showed some inhibitory activity on both enzymes except for compounds 7 and 9, which did not inhibit BChE at the concentrations tested.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.